Valuation: Black Diamond Therapeutics, Inc.

Market Cap 117M 101M 95.37M 86.52M 162M 11.18B 163M 1.14B 439M 5.67B 438M 428M 18.03B P/E 2026 *
-3.29x
P/E 2027 * -2.13x
Enterprise Value 117M 101M 95.37M 86.52M 162M 11.18B 163M 1.14B 439M 5.67B 438M 428M 18.03B EV / Sales 2026 *
18.7x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+2.53%
1 week-4.25%
Current month-3.33%
1 month+0.50%
3 months+16.00%
6 months-4.25%
Current year-16.46%
1 week 1.92
Extreme 1.92
2.15
1 month 1.92
Extreme 1.92
2.32
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.07
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
3/20/26 A
NEA Management Co. LLC
OtherCompany 0 0% -
3/20/26 A Free

Director

6,105 0.0107%
3/20/26 A Free

Director

6,919 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
+2.53%-4.25%-37.54%-43.61% 117M
+5.04%+3.66%+50.62%+103.77% 70.24B
+1.64%-0.18%+34.67%+76.81% 62.63B
-3.18%-0.78%-14.14%+369.82% 27.36B
-0.49%-1.05%+25.59%+11.12% 25.71B
+2.20%-4.72%+2.19%-13.14% 24.83B
+1.15%-1.17%+17.56%-21.92% 19.52B
-7.03%-10.19%+161.91%+303.00% 15.51B
-4.82%-6.15%-10.02%+479.75% 14.66B
+4.96%+4.63%-2.75%+864.40% 14.69B
Average +0.18%-2.07%+22.81%+213.00% 27.53B
Weighted average by Cap. +1.17%-0.81%+31.66%+167.76%

Financials

2026 *2027 *
Net sales 6.25M 5.42M 5.11M 4.64M 8.7M 599M 8.76M 61.04M 23.52M 304M 23.47M 22.96M 966M -
Net income -36.96M -32.03M -30.23M -27.42M -51.44M -3.54B -51.81M -361M -139M -1.8B -139M -136M -5.71B -64.65M -56.02M -52.86M -47.96M -89.97M -6.2B -90.62M -631M -243M -3.14B -243M -237M -9.99B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
14/09/26 $2.030 +2.53% 514,158
11/09/26 $1.980 +1.02% 590,205
10/09/26 $1.960 -6.67% 677,922
09/09/26 $2.100 0.00% 402,592
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.030USD
Average target price
10.00USD
Spread / Average Target
+392.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!